By designing therapies to precisely restore normal flux through disease-affected pathways, we accelerate the development cycle, greatly improve the chances of therapeutic success, and reduce the potential for adverse side effects.

We take advantage of normal biological processes to create desired therapeutic effects by not only modulating the factors controlling key metabolic reactions, but also providing the necessary substrates for the reactions that are activated.

Our unique approach lets us target a wide spectrum of diseases which cannot be addressed by current therapies. Predictive algorithmic modelling has shown a high degree of accuracy in forecasting our clinical trial results.